Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Income Statement
Quarterly Data

Regeneron Pharmaceuticals Inc., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net product sales 2,002,900 1,946,400 1,918,600 1,761,300 1,851,800 1,786,100 1,772,100 1,668,000 1,699,300 1,801,400 1,754,400 1,638,600 3,975,200 2,279,900 4,137,800 1,724,300 1,621,800 1,482,200 1,226,900 1,236,700
Collaboration revenue 1,606,900 1,660,100 1,524,000 1,266,800 1,370,000 1,438,300 1,316,700 1,378,100 1,587,400 1,050,600 1,043,600 1,232,500 890,300 1,073,900 954,700 754,400 677,700 653,200 513,300 528,300
Other revenue 179,400 114,200 104,500 116,900 212,500 138,300 69,300 116,000 127,700 84,200 59,200 94,000 86,200 99,000 46,000 50,000 123,400 158,600 211,800 63,200
Revenues 3,789,200 3,720,700 3,547,100 3,145,000 3,434,300 3,362,700 3,158,100 3,162,100 3,414,400 2,936,200 2,857,200 2,965,100 4,951,700 3,452,800 5,138,500 2,528,700 2,422,900 2,294,000 1,952,000 1,828,200
Cost of goods sold (326,800) (262,300) (257,800) (240,400) (306,800) (224,500) (192,400) (208,400) (302,200) (141,300) (149,200) (207,300) (811,700) (238,800) (539,400) (183,200) (179,600) (131,000) (102,500) (78,800)
Cost of collaboration and contract manufacturing (238,600) (228,800) (222,400) (193,400) (210,200) (211,900) (212,500) (249,100) (238,400) (176,500) (147,900) (197,600) (170,900) (214,400) (154,300) (124,800) (173,500) (143,000) (173,000) (138,500)
Cost of revenues (565,400) (491,100) (480,200) (433,800) (517,000) (436,400) (404,900) (457,500) (540,600) (317,800) (297,100) (404,900) (982,600) (453,200) (693,700) (308,000) (353,100) (274,000) (275,500) (217,300)
Gross profit 3,223,800 3,229,600 3,066,900 2,711,200 2,917,300 2,926,300 2,753,200 2,704,600 2,873,800 2,618,400 2,560,100 2,560,200 3,969,100 2,999,600 4,444,800 2,220,700 2,069,800 2,020,000 1,676,500 1,610,900
Research and development (1,412,100) (1,271,500) (1,200,000) (1,248,400) (1,177,200) (1,075,300) (1,085,300) (1,101,200) (1,043,100) (911,300) (794,300) (843,800) (737,600) (665,400) (714,200) (742,900) (744,500) (684,600) (722,000) (583,900)
Acquired in-process research and development (13,800) (56,200) (23,900) (7,100) (30,000) (100,000) (56,100) (30,000) (197,000) (28,100) (48,000)
Selling, general, and administrative (792,200) (714,400) (758,800) (689,000) (737,700) (640,500) (652,000) (601,100) (660,500) (529,100) (476,300) (450,000) (559,600) (445,000) (414,700) (405,600) (303,500) (326,900) (348,300) (367,300)
Other operating income (expense), net (15,500) (8,000) (14,600) (15,300) 500 500 600 500 6,600 45,700 17,400 20,200 15,800 (42,000) 31,300 40,500 145,200 44,600 50,200 40,400
Income from operations 990,200 1,179,500 1,069,600 751,400 972,900 1,111,000 1,016,500 946,700 1,146,800 1,223,700 1,109,900 1,258,500 2,639,700 1,847,200 3,347,200 1,112,700 1,167,000 1,053,100 656,400 700,100
Other income (expense), net (21,600) 327,300 573,300 (34,600) 193,000 17,600 85,300 (70,700) 195,300 301,400 (133,600) (183,800) (122,200) (16,400) 420,000 154,900 72,400 (28,500) 272,200 (25,400)
Interest expense (10,500) (13,800) (14,800) (16,100) (18,300) (17,800) (18,900) (18,000) (17,400) (15,300) (13,100) (13,600) (14,100) (14,200) (14,400) (14,600) (14,800) (26,300) (9,700) (6,100)
Other income (expense) (32,100) 313,500 558,500 (50,700) 174,700 (200) 66,400 (88,700) 177,900 286,100 (146,700) (197,400) (136,300) (30,600) 405,600 140,300 57,600 (54,800) 262,500 (31,500)
Income before income taxes 958,100 1,493,000 1,628,100 700,700 1,147,600 1,110,800 1,082,900 858,000 1,324,700 1,509,800 963,200 1,061,100 2,503,400 1,816,600 3,752,800 1,253,000 1,224,600 998,300 918,900 668,600
Income tax (expense) benefit (40,400) (152,400) (195,800) 21,300 12,000 (103,000) (114,500) (40,200) (127,600) (194,100) (111,100) (87,600) (274,400) (184,400) (653,900) (137,800) (75,400) (156,200) (21,600) (44,000)
Net income 917,700 1,340,600 1,432,300 722,000 1,159,600 1,007,800 968,400 817,800 1,197,100 1,315,700 852,100 973,500 2,229,000 1,632,200 3,098,900 1,115,200 1,149,200 842,100 897,300 624,600

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Income statement item Description The company
Revenues Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Regeneron Pharmaceuticals Inc. revenues increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Income from operations The net result for the period of deducting operating expenses from operating revenues. Regeneron Pharmaceuticals Inc. income from operations increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Regeneron Pharmaceuticals Inc. income before income taxes decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc. net income decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.